Zuranolone
Författaruppgift saknas
Tidskrift saknas · review PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för zuranolone. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
34 träffarZuranolone.
Beninger P.
Clin Ther · editorial · DOI 10.1016/j.clinthera.2023.11.006Redefining Postpartum Depression Treatment: The Clinical Potential of Zuranolone.
Nashwan AJ, Rehan ST, Imran L, Abbas SG, Khan S.
Asian J Psychiatr · letter · DOI 10.1016/j.ajp.2023.103849Efficacy and safety of zuranolone for the treatment of depression: A systematic review and meta-analysis.
Li Z, Wu Q, Peng P, Wu M, Liu S, Liu T.
Psychiatry Res · meta-analysis; systematic review; journal article · DOI 10.1016/j.psychres.2023.115640Efficacy and safety of zuranolone in major depressive disorder: a meta-analysis of factor effect and dose-response analyses.
Lin YW, Tu YK, Hung KC, Liang CS, Tseng PT, Lin PY, Chia-Cheng Lai E, Hsu CW.
EClinicalMedicine · research-article; journal article · DOI 10.1016/j.eclinm.2023.102308Zuranolone: First Approval.
Heo YA.
Drugs · review; journal article · DOI 10.1007/s40265-023-01953-xEfficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.
Parikh SV, Aaronson ST, Mathew SJ, Alva G, DeBattista C, Kanes S, Lasser R, Bullock A, Kotecha M, Jung J, Forrestal F, Jonas J, Vera T, Leclair B, Doherty J.
Neuropsychopharmacology · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1038/s41386-023-01751-9Zuranolone: The First FDA-Approved Oral Treatment Option for Postpartum Depression.
Barnes KN, Vogl CM, Nelson LA.
Ann Pharmacother · review; journal article · DOI 10.1177/10600280231204953Screening and the New Treatment for Postpartum Depression.
Hawkins SS.
J Obstet Gynecol Neonatal Nurs · review; journal article · DOI 10.1016/j.jogn.2023.09.007Neurosteroids and Postpartum Depression: The Mechanism, Efficacy, and Approval of Brexanolone and Zurzuvae.
Kargbo RB.
ACS Med Chem Lett · editorial · DOI 10.1021/acsmedchemlett.3c00388The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trials.
Zou J, Yang L, Yang G, Gao J.
Psychiatry Res · meta-analysis; research support, non-u.s. gov't; systematic review; journal article · DOI 10.1016/j.psychres.2023.115450Zuranolone Treatment for Depression: Steady Progress in Mechanism-Focused Therapeutics?
Pine DS.
Am J Psychiatry · comment; editorial · DOI 10.1176/appi.ajp.20230537Exploring Novel Therapeutic Approaches for Depressive Disorders: The Role of Allopregnanolone Agonists.
Bhatti NA, Jobilal A, Asif K, Jaramillo Villegas M, Pandey P, Tahir AN, Balla N, Arellano Camargo MP, Ahmad S, Kataria J, Abdin ZU, Ayyan M.
Cureus · review-article; review; journal article · DOI 10.7759/cureus.44038Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder.
Meshkat S, Teopiz KM, Di Vincenzo JD, Bailey JB, Rosenblat JD, Ho RC, Rhee TG, Ceban F, Kwan ATH, Cao B, McIntyre RS.
J Affect Disord · review; journal article; research support, n.i.h., extramural · DOI 10.1016/j.jad.2023.08.027Zuranolone for the Treatment of Postpartum Depression.
Deligiannidis KM, Meltzer-Brody S, Maximos B, Peeper EQ, Freeman M, Lasser R, Bullock A, Kotecha M, Li S, Forrestal F, Rana N, Garcia M, Leclair B, Doherty J.
Am J Psychiatry · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1176/appi.ajp.20220785Clinical specificity profile for novel rapid acting antidepressant drugs.
Scala M, Fanelli G, De Ronchi D, Serretti A, Fabbri C.
Int Clin Psychopharmacol · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.1097/yic.0000000000000488Pharmacokinetics, safety, and tolerability of single and multiple doses of zuranolone in Japanese and White healthy subjects: A phase 1 clinical trial.
Sonoyama T, Shimizu R, Kubota R, Matsuo Y, Okutsu D, Yamanaka H, Takasu K, Ogawa K, Motomiya T.
Neuropsychopharmacol Rep · research support, non-u.s. gov't; research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1002/npr2.12359Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial.
Kato M, Nakagome K, Baba T, Sonoyama T, Okutsu D, Yamanaka H, Shimizu R, Motomiya T, Inoue T.
Psychiatry Clin Neurosci · clinical trial, phase ii; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1111/pcn.13569Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial.
Clayton AH, Lasser R, Parikh SV, Iosifescu DV, Jung J, Kotecha M, Forrestal F, Jonas J, Kanes SJ, Doherty J.
Am J Psychiatry · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1176/appi.ajp.20220459New depression drug zuranolone one step closer to FDA ruling.
Carvalho T.
Nat Med · news · DOI 10.1038/d41591-023-00032-8Zuranolone and its role in treating major depressive disorder: a narrative review.
Ali M, Ullah I, Diwan MN, Aamir A, Awan HA, Waris Durrani A, Qudrat QU, Shoib S, De Berardis D.
Horm Mol Biol Clin Investig · review; journal article · DOI 10.1515/hmbci-2022-0042Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
Clayton AH, Lasser R, Nandy I, Sankoh AJ, Jonas J, Kanes SJ.
J Clin Psychiatry · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.4088/jcp.22m14445Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression.
Deligiannidis KM, Citrome L, Huang MY, Acaster S, Fridman M, Bonthapally V, Lasser R, Kanes SJ.
J Clin Psychiatry · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.4088/jcp.22m14475A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults.
Bullock A, Gunduz-Bruce H, Zammit GK, Qin M, Li H, Sankoh AJ, Silber C, Kanes SJ, Jonas J, Doherty J.
Hum Psychopharmacol · research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1002/hup.2806Allopregnanolone Mediates Affective Switching Through Modulation of Oscillatory States in the Basolateral Amygdala.
Antonoudiou P, Colmers PLW, Walton NL, Weiss GL, Smith AC, Nguyen DP, Lewis M, Quirk MC, Barros L, Melon LC, Maguire JL.
Biol Psychiatry · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.biopsych.2021.07.017Non-superiority of zuranolone (SAGE-217) at the longer-term.
Ten Doesschate F, van Waarde JA, van Wingen GA.
J Affect Disord · letter; comment · DOI 10.1016/j.jad.2021.05.015Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder.
Arnaud A, Suthoff E, Stenson K, Werneburg B, Hodgkins P, Bonthapally V, Jonas J, Meyer K, O'Day K.
J Affect Disord · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jad.2021.02.027Emerging Therapeutics Based on the Amino Acid Neurotransmitter System: An Update on the Pharmaceutical Pipeline for Mood Disorders.
Hecking J, Davoudian PA, Wilkinson ST.
Chronic Stress (Thousand Oaks) · review-article; review; journal article · DOI 10.1177/24705470211020446Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study.
Bullock A, Kaul I, Li S, Silber C, Doherty J, Kanes SJ.
J Neurol Sci · clinical trial, phase ii; journal article · DOI 10.1016/j.jns.2020.117277Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA<sub>A</sub> receptor positive allosteric modulator.
Althaus AL, Ackley MA, Belfort GM, Gee SM, Dai J, Nguyen DP, Kazdoba TM, Modgil A, Davies PA, Moss SJ, Salituro FG, Hoffmann E, Hammond RS, Robichaud AJ, Quirk MC, Doherty JJ.
Neuropharmacology · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.neuropharm.2020.108333